Choosing omalizumab in severe allergic asthma: evidence and practices

Speciality: Pulmonary Medicine


Speaker:

Dr. Venugopal - Speaker | Pulmonologist

Description:

A warm welcome to all the medical professionals in this interesting session on Choosing omalizumab in severe allergic asthma: evidence and practices
Omalizumab, an anti-IgE monoclonal antibody, has become a key treatment for patients with severe allergic asthma who remain uncontrolled despite standard therapies. By targeting IgE, a critical player in allergic responses, omalizumab helps reduce exacerbations, improve lung function, and enhance quality of life. Clinical evidence shows that it is particularly effective in patients with elevated serum IgE levels and frequent asthma attacks.
When choosing omalizumab, physicians consider factors like the patient’s IgE levels, asthma severity, and response to previous treatments. Guidelines support its use in patients with allergic asthma not controlled by inhaled corticosteroids and long-acting beta-agonists. Regular monitoring and patient education are essential, as the treatment is typically administered subcutaneously every 2 to 4 weeks, providing a personalized approach for managing severe asthma.
Therefore, get an overall knowledge of choosing omalizumab in severe allergic asthma: evidence and practices. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

2.

A small rise in cancer was observed following the 1986 Chernobyl accident.

3.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

4.

The hidden costs of cancer for young survivors are derailing their financial futures

5.

Report reveals lung cancer is the leading cause of cancer deaths in Florida


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot